P66Shc is an adaptor protein and one of the cellular fate regulators since it modulates mitogenic signaling pathways, mitochondrial function, and reactive oxygen species (ROS) production. p66Shc is localized mostly in the cytosol and endoplasmic reticulum (ER); however, under oxidative stress, p66Shc is post-translationally modified and relocates to mitochondria. p66Shc was found in the intermembrane space, where it interacts with cytochrome c, contributing to the hydrogen peroxide generation by the mitochondrial respiratory chain. Our previous studies suggested that p66Shc is localized also in mitochondria-associated membranes (MAM). MAM fraction consists of mitochondria and mostly ER membranes. Contact sites between ER and mitochondria host proteins involved in multiple processes including calcium homeostasis, apoptosis, and autophagy regulation. Thus, p66Shc in MAM could participate in processes related to cell fate determination. Due to reports on various and conditional p66Shc intracellular localization, in the present paper, we describe the allocation of p66Shc pools in different subcellular compartments in mouse liver tissue and HepG2 cell culture. We provide additional evidence for p66Shc localization in MAM. In the present study, we use precisely purified subcellular fraction isolated by differential centrifugation-based protocol from control mouse liver tissue and HepG2 cells and from cells treated with hydrogen peroxide to promote mitochondrial p66Shc translocation. We performed controlled digestion of crude mitochondrial fraction, in which the degradation patterns of p66Shc and MAM fraction marker proteins were comparable. Moreover, we assessed the distribution of the individual ShcA isoforms (p46Shc, p52Shc, and p66Shc) in the subcellular fractions and their contribution to the total ShcA in control mice livers and HepG2 cells. In conclusion, we showed that a substantial pool of p66Shc protein resides in MAM in control conditions and after oxidative stress induction.

The carnivorous pitcher plant, Nepenthes × ventrata (Hort. ex Fleming = N. ventricosa Blanco × N. alata Blanco), produces passive traps containing digestive fluid. Although reactive oxygen species (ROS) in the fluid were detected in some pitcher plants, the participation of reactive nitrogen species (RNS) in the digestion process has not yet been examined. The aim of this work was to investigate the production of superoxide anion (O₂^•−), nitric oxide (NO) and peroxynitrite (ONOO⁻) levels in the digestive fluid of traps throughout organ development. We revealed the ROS and RNS occurrence in the digestive fluid, linked to the ROS-scavenging capacity and total phenolics content. In digestive fluid from the fed traps, NO emission was higher than in the fluid from the developed unfed pitcher. The concentration of nitrite (NO₂⁻) decreased in the fluid from the fed traps in comparison to the unfed ones, pointing at NO₂⁻ as the key source of NO. The enhanced emission of NO was associated with lowered content of ONOO⁻ in the fluid, probably due to lower production of O₂^•−. At the same time, despite a decline in total phenolics, the maximum ROS scavenging capacity was detected. In addition, ROS and RNS were noted even in closed traps, suggesting their involvement not only in digestion per se but also their action as signaling agents in trap ontogeny.

Neurodegeneration with brain iron accumulation (NBIA) describes a group of extremely rare hereditary disorders with an estimated prevalence of 1–3/1,000,000. Mitochondrial membrane protein associated neurodegeneration (MPAN) is the third most common form of NBIA, accounting for 10% of NBIA cases globally and up to 50% of cases in Poland. This survey was conducted by the Association NBIA Poland to collect data on the functioning of patients with NBIA/MPAN based on self-reported EQ-5D-5L (EuroQoL 5-Dimension 5-Level) scores. A total of 50 patients living in Poland, including 26 patients with NBIA/MPAN, participated in the study. The mean age of NBIA/MPAN patients was 22 years; the mean age at symptom onset is 10 years. At the time of the survey, most patients were disabled and required assistance with daily activities. More than 50% of participants needed help with hygiene or dressing, and 40% were unable to walk on their own. Nearly 50% of patients declared symptoms indicating lowered mood. The survey showed that NBIA/MPAN leads to significant disability within a short period of time after symptom onset. Intensive work is underway to discover the role of the C19orf12 protein and develop therapeutic strategies. Actions are necessary to improve the comfort of everyday life of patients with NBIA/MPAN and to improve access to rehabilitation, including home-based programmes.

Background: Biomarker analysis in neurodegeneration with brain iron accumulation (NBIA) can offer valuable insights into the disease’s pathology and natural history. Methods: Twenty-five patients with C19orf12 mutations causing mitochondrial membrane protein-associated neurodegeneration (MPAN), 12 patients with PANK2 mutations causing pantothenate kinase-associated neurodegeneration (PKAN), and 30 age- and gender-matched controls were studied. Serum levels of MMP-9, S100B, ICAM-1, E- and P-selectins, total α-synuclein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), Tau, ubiquitin-C-terminal hydrolase-L1 (UCH-L1), and brain-derived neurotrophic factor (BDNF) were measured. Clinical status was evaluated with dedicated rating scales. Results: Compared to the control group, MPAN patients had significantly higher serum levels of nearly all biomarkers, except BDNF. NfL, GFAP, and UCH-L1, were elevated by 5, 2, and 3.5 times, respectively. PKAN patients showed no significant differences in GFAP, UCH-L1, and S100B levels compared to controls. However, NfL and Tau levels were increased by 3 and 1.8 times, respectively. A correlation was observed between disease severity and levels of NfL, Tau, and UCH-L1 in MPAN, and GFAP, Tau, and UCH-L1 in PKAN. Conclusions: Patients with MPAN and PKAN showed increased levels of neurodegeneration biomarkers. Elevated inflammation and blood–brain barrier dysfunction biomarkers were specific to MPAN patients.

Obesity remains one of the most pressing public health challenges in Europe, with substantial health, social, and economic consequences. Despite extensive research and numerous national strategies, obesity prevention efforts remain fragmented across countries, limiting comparability, scalability, and policy impact. The present description introduces the collaborative effort of “ OBEClust ,” a pan‐European initiative designed to harmonize obesity prevention research and policy, fostering collaboration across disciplines, sectors, and countries. OBEClust aims to create a coordinated framework that integrates research methodologies, shared data infrastructures, and knowledge translation approaches to strengthen the evidence base and support the development and implementation of effective and equitable obesity prevention strategies. The initiative brings together researchers, policymakers, and public health stakeholders to standardize core indicators, align evaluation frameworks, and promote evidence‐informed policy development. By facilitating cross‐country collaboration and reducing duplication of efforts, OBEClust seeks to strengthen capacity for prevention research and accelerate the implementation of effective interventions. Through harmonization and structured knowledge exchange, OBEClust addresses existing gaps between scientific evidence and policy action. This initiative provides a collaborative framework for European obesity research coordination that provides a transferable model for cross‐project cooperation through methodological harmonization, structured knowledge exchange, stakeholder engagement, and evidence translation.

Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) is the third most common genetically-defined subtype of Neurodegeneration with Brain Iron Accumulation (NBIA), a group of rare, clinically heterogeneous disorders. The MPAN pathomechanism, including the link between C19orf12 mutations, iron accumulation, and metabolic alterations, is still poorly understood. While earlier research pointed to impaired autophagy in MPAN, a comprehensive understanding remains elusive. Here, we investigated the autophagy-linked proteome in primary fibroblasts derived from 18 MPAN patients and identified distinct alterations in autophagy-related protein expression. Importantly, a subset of these proteomic changes showed significant associations with disease severity, highlighting their potential relevance as biomarkers of clinical progression. Functional analyses further revealed increased lysosomal acidification as the most consistently affected autophagy-related process in MPAN fibroblasts. Notably, both proteomic and functional alterations were associated with C19orf12 mutation zygosity, underscoring its modulatory role in disease-relevant cellular pathways.